Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kurarinone is a naturally occurring prenylated flavanone and a major bioactive component isolated from the roots of Sophora flavescens and other related plants[3][6][7]. It exhibits a broad spectrum of pharmacological activities including antitumor (anticancer), anti-inflammatory, neuroprotective (notably in Parkinson’s disease models), anti-drug resistance, antimicrobial (antifungal and antibacterial), antioxidant, estrogenic effects as well as modulation of metabolic enzymes. Mechanistically, kurarinone acts through multiple pathways such as inhibition of Th1/Th17 cell differentiation via immune modulation[1][9], suppression of STAT3 and Akt signaling pathways[3], selective inhibition of soluble epoxide hydrolase (sEH/Ephx2)[5], and inhibition/modulation of cytochrome P450 enzymes and UDP-glucuronosyltransferases[7]. Kurarinone has shown efficacy in preclinical models for cancer chemoprevention and neurodegenerative diseases like Parkinson’s disease by stabilizing epoxyeicosatrienoic acids through sEH inhibition[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kurarinone.